Advertisement

Oculoplastic Complications of Cancer Therapy

  • Michael A. Connor
  • Bita EsmaeliEmail author
Chapter

Abstract

Many modalities exist for cancer therapy, and like most medical interventions, cancer therapies can produce side effects and complications. Ultimately, the goal in treating cancer is to prolong survival, and side effects are often unavoidable. Careful individualized planning is required to limit the risks and side effects of cancer treatment. The incidence and severity of side effects depend on the treatment method and on individual patient characteristics; for a given treatment, the incidence and severity of side effects can vary widely among patients [1].

Keywords

Lacrimal Gland Secondary Malignancy Nasolacrimal Duct Meibomian Gland Grave Ophthalmopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer. 2006;6(9):702–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Gordon KB, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys. 1995;31(5):1123–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4(9):529–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Stephens LC, Schultheiss TE, Peters LJ, Ang KK, Gray KN. Acute radiation injury of ocular adnexa. Arch Ophthalmol. 1988;106(3):389–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Small W, Woloschak G. Radiation toxicity: a practical guide. New York: Springer; 2006.CrossRefGoogle Scholar
  6. 6.
    Giro C, Berger B, Bokle E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90(2):166–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol. October 2009. 32(5): 472–476.Google Scholar
  8. 8.
    Archambeau J. Relative radiation sensitivity of the integumentary system dose response of the epidermal, microvascular, and dermal populations, vol. 12. San Diego: Academic; 1987.Google Scholar
  9. 9.
    Denham JW, Hamilton CS, Simpson SA, et al. Factors influencing the degree of erythematous skin reactions in humans. Radiother Oncol. 1995;36:107–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Durkin SR, Roos D, Higgs B, Casson RJ, Selva D. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007;85:240–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Simonen P, Hamilton C, Ferguson S, Ostwald P, O’Brien M, O’Brien P, et al. Do inflammatory processes contribute to radiation induced erythema observed in the skin of humans? Radiother Oncol. 1998;46:73–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Burger A, Loffler H, Bamberg M, Rodemann HP. Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol. 1998;73(4):401–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol. 1995;35(2):83–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Hsu A, Frank S, Ballo M, et al. Postoperative adjuvant external-beam radiation therapy for cancers of the eyelid and conjunctiva. Ophthal Plast Reconstr Surg. 2008;24(6):444–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Karp LA, Streeten BW, Cogan DG. Radiation-induced atrophy of the meibomian glands. Arch Ophthalmol. 1979;97(2):303–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Berman A, Rengan R, Tripuraneni P. Radiotherapy for eyelid, periocular and periorbital skin cancers. Int Ophthalmol Clin. 2009;49(4):129–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper JS, Fu K, Marks J, Silverman S. Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys. 1995;31:1141–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys. 1994;30(4):775–80.PubMedCrossRefGoogle Scholar
  19. 19.
    Parsons J, Bova F, Mendenhall W, Million R, Fitzgerald C. Response of the normal eye to high dose radiotherapy. Oncology. 1996;6(10):847–8.Google Scholar
  20. 20.
    Diba R, Saadati H, Esmaeli B. Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck. 2005;27(1):72–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB. Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck. 2002;24(9):821–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Jereczeck-Fossa B, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28:65–74.CrossRefGoogle Scholar
  23. 23.
    Roumanas E, Chang T, Beumer J. Use of osseointegrated implants in the restoration of head and neck defects. J Calif Dent Assoc. 2006;34(9):711–8.PubMedGoogle Scholar
  24. 24.
    Probert J, Parker B. The effect of radiation on bone growth. Radiology. 1975;114:155–62.PubMedGoogle Scholar
  25. 25.
    Raney RB, James RA, Jeffrey K, et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984–1991. Med Pediatr Oncol. 2000;34(6):413–20.PubMedCrossRefGoogle Scholar
  26. 26.
    El-Naggar AM, Hanna IRA, Chanana AD, Arland LC, Cronkite EP. Bone marrow changes after localized acute and fractionated X irradiation. Radiat Res. 1980;84(1):46–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Gevorgyan A, La Scala GC, Neligan PC, Pang CY, Forrest CR. Radiation-induced craniofacial bone growth disturbances. J Craniofac Surg. 2007;18(5):1001–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Heyn R, Ragab A, Raney R, et al. Late effects of therapy in orbital rhabdomyosarcoma in children. A report from the Intergroup Rhabdomyosarcoma Study. Cancer. 1986;57(9):1738–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen I, Diegelmann R, Lindbald W. Wound healing: biochemical and clinical aspects. Philadelphia: Saunders; 1992.Google Scholar
  30. 30.
    Porock D, Nikoletti S, Cameron F. The relationship between factors that impair wound healing and the severity of acute radiation skin and mucosal toxicities in head and neck cancer. Cancer Nurs. 2004;27(1):71–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Hanasono MMMD, Lee JCBA, Yang JSBS, Skoracki RJMD, Reece GPMD, Esmaeli BMD. An algorithmic approach to reconstructive surgery and prosthetic rehabilitation after orbital exenteration. Plast Reconstr Surg. 2009;123(1):98–105.PubMedCrossRefGoogle Scholar
  32. 32.
    Shields JAMD, Shields CLMD, Demirci HMD, Honavar SGMD, Singh ADMD. Experience with eyelid-sparing orbital exenteration: the 2000 Tullos O Coston Lecture. Ophthal Plast Reconstr Surg. 2001;17(5):355–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5(12):943–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Little J. Radiation carcinogenesis. Carcinogenesis. 2000;21:397–404.PubMedCrossRefGoogle Scholar
  35. 35.
    Sale K, Wallace D, Girod D, Tsue T. Radiation-induced malignancy of the head and neck. Otolaryngol Head Neck Surg. 2004;131:643–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Lustig L, Jackler R, Lanser M. Radiation induced tumors of the temporal bone. Am J Otol. 1997;18:230–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Li F, Cassady J, Jaffe N. Risk of second tumors in survivors of childhood cancer. Cancer. 1975;35:1230–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Toda K, Shibuya H, Hayashi K, Aukawa F. Radiation-induced cancer after radiotherapy for non-Hodgkin’s lymphoma of the head and neck: a retrospective study. Radiat Oncol. 2009;4:21–8.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Verellen D, Banhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol. 1999;53:199–203.PubMedCrossRefGoogle Scholar
  40. 40.
    Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62(4):1195–203.PubMedCrossRefGoogle Scholar
  41. 41.
    Miyahara H, Sato T, Yoshino K. Radiation-induced cancer of the head and neck region. Acta Otolaryngol. 1998;533:60–4.CrossRefGoogle Scholar
  42. 42.
    Umatani K, Satoh T, Yoshino K, et al. Radiation-induced cancers of the head and neck (III). Nihon Kikan Shokudoka Gakkai Kaiho. 1989;4(40):313–9.CrossRefGoogle Scholar
  43. 43.
    van der Laan BF, Baris G, Gregor R, et al. Radiation-induced tumours of the head and neck. J Laryngol Otol. 1995;109:346–9.PubMedGoogle Scholar
  44. 44.
    King A, Ahuja A, Teo P, Tse G, Kew J. Radiation induced sarcomas of the head and neck following radiotherapy for nasopharyngeal carcinoma. Clin Radiol. 2000;55:684–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Robinson E, Neugut A, Wylie P. Clinical aspects of postirradiation sarcomas. J Natl Cancer Inst. 1988;80:233–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Mark R, Poen J, Tran L, Selch Y, Parker R. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer. 1994;73:2653–62.PubMedCrossRefGoogle Scholar
  47. 47.
    Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51(1):19–40.PubMedCrossRefGoogle Scholar
  48. 48.
    National registry of drug-induced ocular side effects. http://www.eyedrugregistry.com/. Accessed June 2010.
  49. 49.
    Valero V. Primary chemotherapy with docetaxel for the management of breast cancer. Oncology. 2002;16:35–43.PubMedGoogle Scholar
  50. 50.
    Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001;108(5):994–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98(3):504–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Esmaeli B, Amin S, Valero V, et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006;24(22):3619–22.PubMedCrossRefGoogle Scholar
  53. 53.
    Esmaeli BMD, Burnstine MAMD, Ahmadi MAMD, Prieto VGMDP. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg. 2003;19(4):305–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120(9):1180–2.PubMedCrossRefGoogle Scholar
  55. 55.
    Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol. 2001;119(12):1802–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Christophidis N, Vajda F, Lucas I, Louis W. Ocular side effects with 5-fluorouracil. Aust N Z J Med. 1979;9(2):143–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouracil therapy. Acta Ophthalmol Scand. 2000;78(1):110–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Eiseman ASMD, Flanagan JCMD, Brooks ABMD, Mitchell EPMD, Pemberton CHMD. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg. 2003;19(3):216–24.PubMedCrossRefGoogle Scholar
  59. 59.
    Haidak DJ, Hurwitz BS, Yeung KY. Tear–duct fibrosis (dacryostenosis) due to 5–fluorouracil. Ann Intern Med. 1978;88(5):657–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Hassan A, Hurwitz J, Burkes R. Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol. 1998;33(1):14–9.PubMedGoogle Scholar
  61. 61.
    Fezza J, Wesley R, Klippenstein K. The treatment of punctal and canalicular stenosis in patients on systemic 5-FU. Ophthalmic Surg Lasers. 1999;30(2):105–8.PubMedGoogle Scholar
  62. 62.
    Ng J. Orbital and Periorbital Side Effects of Chemotherapy. In: Ophthalmic Oncology, Esmaeli B, editor. Springer, New York; 2011, p 327–338.Google Scholar
  63. 63.
    Pa S. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs. 2004;15(2):85–106.Google Scholar
  64. 64.
    Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140(2):325–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Kopp E, Seregard S. Epiphora as a side effect of topical mitomycin C. Br J Ophthalmol. 2004;88(11):1422–4.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Billing K, Karagiannis A, Selva D. Punctal-canalicular stenosis associated with mitomycin-C for corneal epithelial dysplasia. Am J Ophthalmol. 2003;136(4):746–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006;90(7):819–22.PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Kloos R, Duvuuri V, Jhaing S, Cahill K, Foster J, Burns J. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:5817–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Shepler T, Sherman S, Faustina M, Busaidy N, Ahmadi M, Esmaeli B. Nasolacrimal duct obstruction associated with radioactive idodine therapy for thyroid carcinoma. Ophthal Plast Reconstr Surg. 2003;19(6):479–81.PubMedCrossRefGoogle Scholar
  70. 70.
    Burns J, Morgenstern K, Cahill K, Foster J, Jhiang S, Kloos R. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg. 2004;20(2):126–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Morgenstern K, Vadysirisack D, Zhang Z, et al. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthal Plast Reconstr Surg. 2005;21(5):337–44.PubMedCrossRefGoogle Scholar
  72. 72.
    Vaccaro M, Pollicino A, Barbuzza O, Guarneri B. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol. 2009;34(3):402–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Papadopoulos R, Chasapi V, Bachariou A. Trichomegaly induced by erlotinib. Orbit. 2008;27(4):329–30.PubMedCrossRefGoogle Scholar
  74. 74.
    Bouche O, Brixi-Benmansour H, Bertin A, Perceau G, Lagarde S. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol. 2005;16(10):1711–2.PubMedCrossRefGoogle Scholar
  75. 75.
    Esmaeli B, Diba R, Ahmadi M, et al. Periorbital edema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (London). 2004;10:760–2.CrossRefGoogle Scholar
  76. 76.
    Fraunfelder F, Solomon J, Druker B, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19:371–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Esmaeli B, Prieto V, Butler C, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881–7.PubMedCrossRefGoogle Scholar
  78. 78.
    McClelland C, Harocopos G, Custer P. Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol. 2010;4:427–31.PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Ganly I, Patel SG, Singh B, et al. Craniofacial resection for malignant paranasal sinus tumors: report of an international collaborative study. Head Neck. 2005;27(7):575–84.PubMedCrossRefGoogle Scholar
  80. 80.
    Akinsola F, Somefun A, Oguntoyinbo O. Ophthalmological complications of nasal, paranasal sinus diseases and head and neck tumours. East Afr Med J. 2006;12(83):674–8.Google Scholar
  81. 81.
    Iannetti G, Valentini V, Rinna C, Ventucci E, Marianetti TM. Ethmoido-orbital tumors: our experience. J Craniofac Surg. 2005;16(6):1085–91.PubMedCrossRefGoogle Scholar
  82. 82.
    Imola MJ, Schramm J, Victor L. Orbital preservation in surgical management of sinonasal malignancy. Laryngoscope. 2002;112(8):1357–65.PubMedCrossRefGoogle Scholar
  83. 83.
    Carrau R, Segas J, Nuss D, et al. Squamous cell carcinoma of the sinonasal tract invading the orbit. Laryngoscope. 1999;109:230–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Nazar G, Rodrigo J, Llorente J, Baragano L, Suarez C. Prognostic factors of maxillary sinus malignancies. Am J Rhinol. 2004;18(4):233–8.PubMedGoogle Scholar
  85. 85.
    Han JK, Higgins TS. Management of orbital complications in endoscopic sinus surgery. Curr Opin Otolaryngol Head Neck Surg. 2010;18(1):32–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Hurwitz J. Dacryocystorhinostomy. Philadelphia: Lippincott-Raven; 1996.Google Scholar
  87. 87.
    Part X Lacrimal disease and surgery. In: Nesi F, Levine M, Lisman R, editors. Smith’s ophthalmic plastic and reconstructive surgery. 2nd ed. St. Louis: Mosby-Year Book, Inc.; 1998, p 639–678.Google Scholar
  88. 88.
    Cook B, Bartley G. Epidemiologic characteristics and clinical course of patients with malignant eyelid tumors in an incidence cohort in Olmstead County, Minnesota. Ophthalmology. 1999;106:746–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Section of Ophthalmology, Department of Head and Neck SurgeryThe University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Ophthalmic Plastic and Reconstructive SurgeryTexas Oculoplastic ConsultantsAustinUSA

Personalised recommendations